The Complexity of the Blood-Brain Barrier and the Concept of Age-Related Brain Targeting: Challenges and Potential of Novel Solid Lipid-Based Formulations.

Autor:	Sommonte F; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy., Arduino I; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy., Racaniello GF; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy., Lopalco A; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy., Lopedota AA; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy., Denora N; Department of Pharmacy - Pharmaceutical Sciences, University of Bari 'Aldo Moro', 4 Orabona St., 70125, Bari, Italy. Electronic address: nunzio.denora@uniba.it.
Jazyk:	angličtina
Zdroj:	Journal of pharmaceutical sciences [J Pharm Sci] 2022 Mar; Vol. 111 (3), pp. 577-592. Date of Electronic Publication: 2021 Aug 29.
DOI:	10.1016/j.xphs.2021.08.029
Abstrakt:	Diseases that affect the Central Nervous System (CNS) are one of the most exciting challenges of recent years, as they are ubiquitous and affect all ages. Although these disorders show different etiologies, all treatments share the same difficulty represented by the Blood-Brain Barrier (BBB). This barrier acts as a protective system of the delicate cerebral microenvironment, isolating it and making extremely arduous delivering drugs to the brain. To overtake the obstacles provided by the BBB it is essential to explore the changes that affect it, to understand how to exploit these findings in the study and design of innovative brain targeted formulations. Interestingly, the concept of age-related targeting could prove to be a winning choice, as it allows to consider the type of treatment according to the different needs and peculiarities depending on the disease and the age of onset. In this review was considered the prospective contribution of lipid-based formulations, namely Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs), which have been highlighted as able to overcome some limitations of other innovative approaches, thus representing a promising strategy for the non-invasive specific treatment of CNS-related diseases. (Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu